Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22864048 | 0.84 | ADRB2 (0.46) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| SCHEMBL22864072 | 0.84 | ADRB2 (0.56) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| SCHEMBL22864047 | 0.83 | ADRB2 (0.47) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| SCHEMBL24631008 | 0.81 | ADRB2 (0.45) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| SCHEMBL24630985 | 0.76 | ADRB2 (0.47) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| SCHEMBL7980035 | 0.75 | MEN1 (0.42) | MEN1KMT2A | |
| SCHEMBL24631022 | 0.74 | ADRB2 (0.55) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| SCHEMBL22480735 | 0.74 | HIF1A (0.56) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| SCHEMBL22481180 | 0.74 | HIF1A (0.56) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| SCHEMBL22493460 | 0.74 | HIF1A (0.56) | ADRB2ADRB1CYP2D6HIF1ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021003161-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885CYP2D6 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.